Reply to: "What Is in a Name"

Mov Disord. 2024 Sep;39(9):1652-1653. doi: 10.1002/mds.29944.

Authors

Christine Brefel-Courbon^{1

2}, Ana Marques³, Olivier Rascol^{1

2}; NS‐Park OXYDOPA study group

Affiliations

¹ Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre, Centre d'Investigation Clinique CIC1436, University Hospital of Toulouse, NeuroToul COEN Centre, Toulouse, France.
² Toulouse NeuroImaging Centre (ToNIC-UMR1214 INSERM/UT3), Toulouse, France.
³ Department of Neurology, CHU Clermont-Ferrand, Université Clermont-Auvergne, CNRS, IGCCN, Institut Pascal, NS-PARK/FCRIN Network, Clermont Ferrand, France.

PMID: 39441144
DOI: 10.1002/mds.29944

No abstract available

Publication types

Letter